Source: Annual Congress 2006 - Mechanisms of respiratory diseases
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Reichenberger, R. Vosswinckel, B. Enke, E. Steveling, A. Kreckel, H. Gall, M. Thamm, H. Olschewski, F. Grimminger, W. Seeger, H. A. Ghofrani (Giessen, Germany; Graz, Austria). Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006; 28: Suppl. 50, 3789

Member's Comments

No comment yet.

Related content which might interest you: Iloprost treatment in portopulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Sildenafil treatment for portopulmonary hypertension Source: Eur Respir J 2006; 28: 563-567 Year: 2006 Experience with inhaled iloprost and bosentan in portopulmonary hypertension Source: Eur Respir J 2007; 30: 1096-1102 Year: 2007 Sildenafil for patients with portopulmonary hypertension, candidates to hepatic transplant Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004 Inhaled iloprost for patients with portopulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 462s Year: 2003 Long-term outcome of patients with portopulmonary hypertension treated with sildenafil Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2015; 46: 405-413 Year: 2015 Portopulmonary hypertension Source: Virtual Congress 2021 – Pulmonary vascular diseases Year: 2021 Ambrisentan for therapy of portopulmonary hypertension (POPH): Update on safety and efficacy Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Efficacy and safety of tadalafil in portopulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension Source: Eur Respir J 2013; 41: 96-103 Year: 2013 Portopulmonary hypertension Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-39-1, page=129 Year: 2005 Development of hepatopulmonary syndrome during combination therapy for portopulmonary hypertension Source: Eur Respir J, 53 (1) 1801880; 10.1183/13993003.01880-2018 Year: 2019 PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension Source: Eur Respir J 2007; 29: 220-221 Year: 2007 How should we treat portopulmonary hypertension? Source: Eur Respir J 2006; 28: 466-467 Year: 2006 Sildenafil and aerolized iloprost treatment in two cases with primary pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 520s Year: 2005 Bosentan therapy for portopulmonary hypertension Source: Eur Respir J 2005; 25: 502-508 Year: 2005 Combination therapy with sildenafil and sitaxentan therapy for pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008 An autopsy case of portopulmonary hypertension associated with idiopathic portal hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II Year: 2013 Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2007; 30: 922-927 Year: 2007